Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological first line treatment in primary care for patients with moderate to severe depression. DESIGN: A multiple treatment comparison meta-analysis was employed to determine the relative efficacy in terms of remission of 10 antidepressants (citalopram, duloxetine escitalopram, fluoxetine, fluvoxamine mirtazapine, paroxetine, reboxetine, sertraline and venlafaxine). The estimated remission rates were then applied in a decision-analytic model in order to estimate costs and quality of life with different treatments at one year. DATA SOURCES: Meta-analyses of remission rates from randomised controlled trials, and cost and quality-of-life data from published sources. RESULTS: The most favourable pharmacological treatment in terms of remission was escitalopram with an 8- to 12-week probability of remission of 0.47. Despite a high acquisition cost, this clinical effectiveness translated into escitalopram being both more effective and having a lower total cost than all other comparators from a societal perspective. From a healthcare perspective, the cost per QALY of escitalopram was €3732 compared with venlafaxine. CONCLUSION: Of the investigated antidepressants, escitalopram has the highest probability of remission and is the most effective and cost-effective pharmacological treatment in a primary care setting, when evaluated over a one year time-horizon. Small differences in remission rates may be important when assessing costs and cost-effectiveness of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 3×
“To assess the inconsistency in the network metaanalysis, the node-splitting techniques explained in Dias et al [16] have been used.”
MethodInfluentialCipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“The average time until remission and relapse as well as the effect of second and third line treatment were taken from a large naturalistic outcomes study of sequenced treatment of depression in primary care [18–20].”
BackgroundA systematic review of the mortality of depression
Wulsin, L. R., Vaillant, G. E., & Wells, V. E. (1999) · Psychosomatic Medicine · doi:10.1097/00006842-199901000-00003 · Cited by 703 · cited 1×
“systematic reviews have shown that for patients in primary care the risk may be 2–6% or lower [26,27].”
BackgroundKeller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 1×
“There is substantial support in the literature that remission is the preferred endpoint due to its clinical relevance and close relation to resource utilization [9,10].”
BackgroundCost of depression: effect of adherence and treatment response
von Knorring, L., Åkerblad, A.-C., Bengtsson, F., Carlsson, Å., & Ekselius, L. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.04.005 · Cited by 58 · cited 1×
“These data were corroborated by another Swedish primary care study which had used response rather than remission as endpoint [22].”
Result
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“In a recent metaanalysis of 10 antidepressants including paroxetine and sertraline for their remission rates, escitalopram was reported to have the most favorable treatment effect, with a remission probability of 0.47 after an 8- to 12-week treatment (Ramsberg et al., 2012).”
BackgroundInfluentialKriston, L., von Wolff, A., Westphal, A., Hölzel, L. P., & Härter, M. (2014) · Depression and Anxiety · doi:10.1002/da.22236 · Cited by 119
De Crescenzo, F., Perelli, F., Armando, M., & Vicari, S. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.019 · Cited by 114
“Response and remission rates demonstrated the efficacy of two SSRIs, paroxetine and sertraline, but none of the trials included escitalopram, which has demonstrated to be the most effective and cost-effective pharmacological treatment in primary care setting in MDD (Ramsberg et al., 2012).”
BackgroundGreenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Metadata
- Authors
- Ramsberg, J., Asseburg, C., & Henriksson, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-02
- Volume
- 7
- Issue
- 8
- Pages
- e42003
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2078288176
- Cited by
- 57
- References
- 6
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model. https://app.cochat.ai/papers/10.1371/journal.pone.0042003
- The paper
- Ramsberg, J., Asseburg, C., & Henriksson, M. (2012). Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model. PLoS ONE. https://doi.org/10.1371/journal.pone.0042003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.